Thursday, 21 March 2019

Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

Pfizer has agreed to pay German biotech firm BioNTech up to $425 million (£334.33 million) in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach.

Privately-held BioNTech will receive $120 million upfront plus up to $305 million depending on certain development achievements as well as tiered royalties on futures sales in the double-digit percentage range, the two companies said in a statement on Thursday.

Mainz-based BioNTech, valued at $2.3 billion in a January financing round, is specialising in so-called messenger RNA (mRNA) molecules that instruct human cells to produce therapeutic proteins or to launch an immune response.

The emergent field has seen drugmakers such as AstraZeneca , Eli Lilly and Sanofi partner up with biotech firms.

“mRNA vaccines offer a novel approach to code for any protein or multiple proteins, and the potential to manufacture higher potency flu vaccines more rapidly and at a lower cost than contemporary flu vaccines,” said Kathrin Jansen, the head of Pfizer’s vaccine research and development unit.

Check Also

Indian billionaire pays million to Ericsson in face of jail

An heir to rags-to-riches billionaire Dhirubhai Ambani, Anil, has been entangled in a Bollywood-like feud ...

Leave a Reply